Serum Institute of India Ltd. has established it's self as the world's largest producer of Measles and DTP group of vaccines. It is estimated that two out of every three children immunized in the world is vaccinated by a vaccine manufactured by Serum Institute. In fact, our range of products have been used in 140 countries across the globe.
Serum Institute of India was founded in 1966 with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps and Rubella) group of vaccines. Headquarters is located at Pune, India.
Basic Information
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Whole Time Director
Purchase this report to view the information.
Whole Time Director
Purchase this report to view the information.
Whole Time Director
Ownership Details
Purchase this report to view the information.
67.33%
Purchase this report to view the information.
9.98%
Purchase this report to view the information.
8.86%
Purchase this report to view the information.
5.24%
Purchase this report to view the information.
5%
Subsidiaries
Company Performance
Financial values in the chart are available after Serum Institute of India Pvt. Ltd. report is purchased.
Looking for more than just a company report?
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency INR. Absolute financial data is included in the purchased report.
Total operating revenue
1.17%▲
Operating profit (EBIT)
-3.3%▼
Net Profit (Loss) for the Period
-0.04%▼
Operating Profit Margin (ROS)
-4.09%▼
Net Profit Margin
-1.66%▼
Return on Equity (ROE)
-1.72%▼
Debt to Equity Ratio
-0.62%▼